A drug used to treat Erdheim-Chester disease (a very rare type of histiocytosis) and advanced melanoma that have a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Vemurafenib blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called BRAF (V600E) kinase inhibitor RO5185426, PLX4032, RG7204, and Zelboraf. US Brand Name(s): Zelboraf. FDA Approved: Yes
Are you looking for or in search of FDA approved “Vemurafenib tablet in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for melanoma. Need Access of “Vemurafenib tablet” for oral use for oral use, get in touch with our healthcare professional.
Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011, making it the first drug designed using fragment-based lead discovery to gain regulatory approval.
Vemurafenib later received Health Canada approval on February 15, 2012. On February 20, 2012, the European Commission approved vemurafenib as a monotherapy for the treatment of adult patients with BRAF V600E mutation positive unresectable or metastatic melanoma, the most aggressive form of skin cancer. On November 6, 2017, the FDA approved Vemurafenib for the treatment of some patients with Erdheim–Chester disease (ECD), a rare type of histiocytic neoplasm.
Vemurafenib is approved to treat patients whose cancer has a certain mutation in the BRAF gene, including:
Melanoma that cannot be removed by surgery or has spread to other parts of the body.